myTomorrows Secures $29 Million to Revolutionize Patient Access to Therapies

myTomorrows Secures $29 Million

In a significant development for patient care, myTomorrows, a pioneering health tech firm, has announced the successful closing of a $29 million investment deal with Avego. This funding is set to drive the expansion of myTomorrows' unique platform, dedicated to connecting patients with various pre-approval treatment options, which include clinical trials and expanded access programs.

Addressing a Critical Need in Healthcare

Currently, there are over 300 million patients around the world grappling with health conditions that lack approved treatment options. With countless therapies in the pipeline, many patients are left in the dark about emerging options that could potentially help them. myTomorrows strives to bridge this gap, ensuring that advancements in science translate into real-world benefits for patients.

The investment from Avego will not only facilitate myTomorrows' growth internationally but will also enhance its AI-powered platform, allowing seamless connections among patients, physicians, clinical trial sites, and Biopharma partners. This integrated approach aims to streamline access to treatments while generating valuable real-world data that can support clinical operations and regulatory decision-making.

Quotes from Leadership

Michel van Harten, the CEO of myTomorrows, highlighted the transformative nature of this funding: "This investment is pivotal in our mission to offer equitable access to innovative therapies for every patient, regardless of their location. Avego’s expertise will be crucial as we enhance our platform and extend our outreach within the healthcare ecosystem."

James Flexner, Managing Partner at Avego, echoed this sentiment, stating, "Avego is proud to back myTomorrows as it redefines the accessibility of therapies in development. We are confident that their model will eliminate barriers for both patients and providers, thereby acting as an essential ally for Biopharma partners."

Ronald Brus, the founder of myTomorrows, remarked on how their journey began in 2012 with the vision of connecting patients to promising therapies—a vision that this investment will help realize on a larger scale. "This marks the beginning of an exciting new chapter for us, amplifying the impact we can have on healthcare worldwide."

Innovative Solutions for a Complex Problem

myTomorrows champions an innovative approach that combines advanced artificial intelligence with professional guidance to assist patients and healthcare providers navigate the labyrinth of treatment options. To date, the platform has aided over 16,900 patients across 133 countries, providing them with critical information and access to treatments that were previously out of reach.

For BioPharma partners, myTomorrows offers solutions for clinical trial recruitment and real-world data collection, essential for developing effective treatment pathways. The integration of all stakeholders in the healthcare landscape ensures that information flows smoothly, thereby increasing trial visibility and enhancing patient experiences.

As a frontrunner in pre-approval therapy access, myTomorrows is set to redefine treatment availability in a new era defined by intelligent processes and patient empowerment. The firm's infrastructure incorporates adaptive regulations and direct patient involvement, ensuring that necessary treatments reach those in urgent need—precisely when it counts the most.

Conclusion

In summary, myTomorrows' significant capital infusion from Avego represents a transformative moment in the healthcare sector. By leveraging innovative technology and industry collaborations, myTomorrows is committed to championing patient access to groundbreaking therapies and making strides towards a more inclusive healthcare future.

For more information about myTomorrows, visit myTomorrows.com.

About myTomorrows

This Amsterdam-based company is dedicated to improving patient access to essential pre-approval treatments through an advanced multi-stakeholder platform. By blending AI insights with human expertise, myTomorrows aims to dismantle existing barriers to treatment accessibility, enhancing patient outcomes while bolstering drug development efficacy.

About Avego

Founded in 2015, Avego is committed to advancing healthcare accessibility through innovative investments. With a focus on fostering growth in both private and public health-related enterprises, Avego plays a crucial role in the transformation of patient care methods.